STERIS plc (NYSE:STE – Free Report) – Equities research analysts at Zacks Research increased their Q3 2026 earnings estimates for STERIS in a note issued to investors on Thursday, June 12th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.65 for the quarter, up from their previous forecast of $2.53. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q4 2026 earnings at $2.86 EPS, FY2026 earnings at $10.36 EPS, Q4 2027 earnings at $2.78 EPS and FY2028 earnings at $12.38 EPS.
STE has been the subject of a number of other research reports. Stephens reiterated an “overweight” rating and issued a $250.00 target price on shares of STERIS in a report on Thursday, May 15th. JMP Securities lifted their price objective on shares of STERIS from $265.00 to $280.00 and gave the stock a “market outperform” rating in a research note on Friday, May 16th. Morgan Stanley increased their target price on shares of STERIS from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Monday, May 19th. Citigroup restated an “outperform” rating on shares of STERIS in a report on Friday, May 16th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Monday, April 7th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and an average target price of $263.83.
STERIS Trading Down 0.5%
Shares of NYSE STE opened at $241.16 on Monday. STERIS has a 1-year low of $200.98 and a 1-year high of $252.79. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. The business’s 50 day moving average is $232.76 and its two-hundred day moving average is $222.76. The stock has a market capitalization of $23.72 billion, a P/E ratio of 51.20 and a beta of 0.94.
STERIS (NYSE:STE – Get Free Report) last posted its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.15. STERIS had a net margin of 8.66% and a return on equity of 13.91%. The firm had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.47 billion. During the same period in the previous year, the firm posted $2.58 EPS. The business’s quarterly revenue was up 5.7% on a year-over-year basis.
STERIS Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th will be given a $0.57 dividend. The ex-dividend date of this dividend is Tuesday, June 10th. This represents a $2.28 annualized dividend and a yield of 0.95%. STERIS’s dividend payout ratio (DPR) is 36.77%.
Insider Activity at STERIS
In other news, SVP Cary L. Majors sold 12,828 shares of the company’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,843,909.76. This represents a 53.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel A. Carestio sold 17,626 shares of STERIS stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $242.56, for a total transaction of $4,275,362.56. Following the transaction, the chief executive officer now directly owns 51,385 shares in the company, valued at approximately $12,463,945.60. The trade was a 25.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.
Institutional Investors Weigh In On STERIS
A number of institutional investors have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. lifted its position in shares of STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares during the last quarter. Avalon Trust Co purchased a new position in shares of STERIS in the 4th quarter worth approximately $30,000. Human Investing LLC bought a new position in shares of STERIS during the 4th quarter worth approximately $31,000. Grove Bank & Trust lifted its position in STERIS by 4,733.3% during the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 142 shares during the last quarter. Finally, Anfield Capital Management LLC lifted its position in STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 91 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.
STERIS Company Profile
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Five stocks we like better than STERIS
- 5 discounted opportunities for dividend growth investors
- RH Stock Rockets on Surprise Profit and Tariff Shift
- 3 Dividend Kings To Consider
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- What is the NASDAQ Stock Exchange?
- Alphabet Enters a Bull Market: Is It Time to Buy?
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.